Mathematical Modelling of the Inhibitory Role of Regulatory T Cells in Tumor Immune Response

The immune system against tumors acts through a complex dynamical process showing a dual role. On the one hand, the immune system can activate some immune cells to kill tumor cells (TCs), such as cytotoxic T lymphocytes (CTLs) and natural killer cells (NKs), but on the other hand, more evidence shows that some immune cells can help tumor escape, such as regulatory T cells (Tregs). In this paper, we propose a tumor immune interaction model based on Tregs-mediated tumor immune escape mechanism. When helper T cells’ (HTCs) stimulation rate by the presence of identified tumor antigens is below critical value, the coexistence (tumor and immune) equilibrium is always stable in its existence region. When HTCs stimulation rate is higher than the critical value, the inhibition rate of effector cells (ECs) by Tregs can destabilize the coexistence equilibrium and cause Hopf bifurcations and produce a limit cycle. This model shows that Tregs might play a crucial role in triggering the tumor immune escape. Furthermore, we introduce the adoptive cellular immunotherapy (ACI) and monoclonal antibody immunotherapy (MAI) as the treatment to boost the immune system to fight against tumors. The numerical results show that ACI can control TCs more, while MAI can delay the inhibitory effect of Tregs on ECs. The result also shows that the combination of both immunotherapies can control TCs and reduce the inhibitory effect of Tregs better than a single immunotherapy can control.

[1]  C. Chen,et al.  Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancer , 2016, Oncotarget.

[2]  George Coukos,et al.  T-regulatory cells: key players in tumor immune escape and angiogenesis. , 2012, Cancer research.

[3]  A. d’Onofrio A general framework for modeling tumor-immune system competition and immunotherapy: Mathematical analysis and biomedical inferences , 2005, 1309.3337.

[4]  S. Quezada,et al.  Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. , 2006, Current opinion in immunology.

[5]  Y. Lai,et al.  The Roles of CD4+ T Cells in Tumor Immunity , 2011 .

[6]  Doron Levy,et al.  A Mathematical Model of the Enhancement of Tumor Vaccine Efficacy by Immunotherapy , 2012, Bulletin of mathematical biology.

[7]  T. Mak,et al.  Immunologic Self-Tolerance Maintained by Cd25+Cd4+Regulatory T Cells Constitutively Expressing Cytotoxic T Lymphocyte–Associated Antigen 4 , 2000, The Journal of experimental medicine.

[8]  Loise M. Francisco,et al.  The PD‐1 pathway in tolerance and autoimmunity , 2010, Immunological reviews.

[9]  Yasuhiro Takeuchi,et al.  Mathematical modeling on helper T cells in a tumor immune system , 2013 .

[10]  J. Liu,et al.  Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor , 2017, Nature Immunology.

[11]  Tongqian Zhang,et al.  The stationary distribution of a microorganism flocculation model with stochastic perturbation , 2020, Appl. Math. Lett..

[12]  Meng Liu,et al.  Analysis of a stochastic tumor-immune model with regime switching and impulsive perturbations , 2020 .

[13]  Gideon Blumenthal,et al.  FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy , 2016, The oncologist.

[14]  B. Levine,et al.  The PDL1-PD1 Axis Converts Human TH1 Cells into Regulatory T Cells , 2011, Science Translational Medicine.

[15]  A. Albert,et al.  Tumors and the immune system: the effects of a tumor growth modulator☆ , 1980 .

[16]  Yan Yang,et al.  Tumour chemotherapy strategy based on impulse control theory , 2017, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences.

[17]  D. Kirschner,et al.  Modeling immunotherapy of the tumor – immune interaction , 1998, Journal of mathematical biology.

[18]  N. Rashevsky Suggestions for a mathematical biophysics of some psychoses. , 1947, The Bulletin of mathematical biophysics.

[19]  Hiroyoshi Nishikawa,et al.  Regulatory T cells: a potential target in cancer immunotherapy , 2018, Annals of the New York Academy of Sciences.

[20]  R. Durrett,et al.  Ordinary Differential Equation Models for Adoptive Immunotherapy , 2018, Bulletin of mathematical biology.

[21]  Roberto Barbuti,et al.  Tumour suppression by immune system through stochastic oscillations. , 2010, Journal of theoretical biology.

[22]  Magda Galach,et al.  DYNAMICS OF THE TUMOR—IMMUNE SYSTEM COMPETITION—THE EFFECT OF TIME DELAY , 2003 .

[23]  Min Yu,et al.  Dual role of delay effects in a tumour–immune system , 2017, Journal of biological dynamics.

[24]  C. Voena,et al.  Advances in cancer immunology and cancer immunotherapy. , 2016, Discovery medicine.

[25]  Y. Takeuchi,et al.  Mathematical modeling and bifurcation analysis of pro- and anti-tumor macrophages , 2020 .

[26]  Gang Huang,et al.  Dynamics in a tumor immune system with time delays , 2015, Appl. Math. Comput..

[27]  Yasuhiro Takeuchi,et al.  Complicated dynamics of tumor-immune system interaction model with distributed time delay , 2020 .

[28]  Svetlana Bunimovich-Mendrazitsky,et al.  Mathematical Model of Pulsed Immunotherapy for Superficial Bladder Cancer , 2008, Bulletin of mathematical biology.

[29]  B. Foster,et al.  Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade. , 2000, Cancer research.

[30]  M. Delitala,et al.  How combination therapies shape drug resistance in heterogeneous tumoral populations , 2018 .

[31]  O. Sotolongo-Costa,et al.  Behavior of tumors under nonstationary therapy , 2002 .

[32]  A. Radunskaya,et al.  Mathematical Modeling of Tumor Immune Interactions: A Closer Look at the Role of a PD-L1 Inhibitor in Cancer Immunotherapy , 2018 .

[33]  Michael S. Kuhns,et al.  CTLA-4: new insights into its biological function and use in tumor immunotherapy , 2002, Nature Immunology.

[34]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[35]  A. Radunskaya,et al.  Mixed Immunotherapy and Chemotherapy of Tumors: Modeling, Applications and Biological Interpretations , 2022 .

[36]  Jason T. George,et al.  Stochastic modeling of tumor progression and immune evasion. , 2018, Journal of theoretical biology.

[37]  P. Bruggen,et al.  Human tumor antigens recognized by T lymphocytes , 1996, The Journal of experimental medicine.

[38]  Helen M. Byrne,et al.  A mathematical model of cytotoxic and helper T cell interactions in a tumour microenvironment , 2018 .

[39]  Y. Horio [Management of Toxicities of Immune Checkpoint Inhibitors]. , 2017, Gan to kagaku ryoho. Cancer & chemotherapy.

[40]  Zhichao Jiang,et al.  Global dynamics of a model for treating microorganisms in sewage by periodically adding microbial flocculants. , 2019, Mathematical biosciences and engineering : MBE.

[41]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[42]  M Tubiana,et al.  Measuring progress against cancer in Europe: has the 15% decline targeted for 2000 come about? , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

[43]  Yuri A. Kuznetsov,et al.  MATCONT: a Matlab package for numerical bifurcation analysis of ODEs , 2004, SIGS.

[44]  Hermann B. Frieboes,et al.  Mathematical modeling of tumor-immune cell interactions. , 2019, Journal of theoretical biology.

[45]  G. Freeman,et al.  PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. , 2013, The Journal of clinical investigation.

[46]  Xiaofeng Han,et al.  Dynamics analysis of a delayed virus model with two different transmission methods and treatments , 2020, Advances in Difference Equations.